Abstract
The binding of propranolol enantiomers to human albumin (ALB), alpha 1-acid glycoprotein (alpha 1-AGP) and plasma was studied. (-) propranolol is more bound than (+)propranolol to alpha 1-AGP (P less than 0.001) and to plasma (P less than 0.05). In solutions containing ALB at a constant concentration (580 mumol/l) and alpha 1-AGP at increasing concentrations, the binding of both isomers increases but the stereo selectivity is evident throughout the alpha 1-AGP concentration range examined (25-100 mumol/l).
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Albani F., Riva R., Baruzzi A. Simple and rapid determination of propranolol and its active metabolite, 4-hydroxypropranolol, in human plasma by liquid chromatography with fluorescence detection. J Chromatogr. 1982 Mar 12;228:362–365. doi: 10.1016/s0378-4347(00)80455-7. [DOI] [PubMed] [Google Scholar]
- Anlezark G., Horton R., Meldrum B. The anticonvulsant action of the (-)- and (+)-enantiomers of propranolol. J Pharm Pharmacol. 1979 Jul;31(7):482–483. doi: 10.1111/j.2042-7158.1979.tb13563.x. [DOI] [PubMed] [Google Scholar]
- Bai S. A., Walle U. K., Wilson M. J., Walle T. Stereoselective binding of the (-)-enantiomer of propranolol to plasma and extravascular binding sites in the dog. Drug Metab Dispos. 1983 Jul-Aug;11(4):394–395. [PubMed] [Google Scholar]
- George C. F., Fenyvesi T., Conolly M. E., Dollery C. T. Pharmacokinetics of dextro-, laevo- and racemic propranolol in man. Eur J Clin Pharmacol. 1972 Mar;4(2):74–76. doi: 10.1007/BF00562500. [DOI] [PubMed] [Google Scholar]
- Jackman G. P., McLean A. J., Jennings G. L., Bobik A. No stereoselective first-pass hepatic extraction of propranolol. Clin Pharmacol Ther. 1981 Sep;30(3):291–296. doi: 10.1038/clpt.1981.162. [DOI] [PubMed] [Google Scholar]
- Jaillon P., Hecklé J., Weissenburger J., Cheymol G. Cardiac electrophysiologic properties of dl-propranolol, d-propranolol, l-propranolol and dl-pindolol in anesthetized dogs. J Pharmacol Exp Ther. 1980 Feb;212(2):347–353. [PubMed] [Google Scholar]
- Kawashima K., Ishikawa H. Pharmacokinetics of propranolol isomers and their relationships with beta adrenoceptor blocking activity in rabbits administered with dl-propranolol. J Pharmacol Exp Ther. 1980 Jun;213(3):628–631. [PubMed] [Google Scholar]
- Müller W. E., Wollert U. High stereospecificity of the benzodiazepine binding site on human serum albumin. Studies with d- and l-oxazepam hemisuccinate. Mol Pharmacol. 1975 Jan;11(1):52–60. [PubMed] [Google Scholar]
- Powis G. The binding of catecholamines to human serum proteins. Biochem Pharmacol. 1975 Mar 15;24(6):707–712. doi: 10.1016/0006-2952(75)90247-6. [DOI] [PubMed] [Google Scholar]
- Silber B., Holford N. H., Riegelman S. Stereoselective disposition and glucuronidation of propranolol in humans. J Pharm Sci. 1982 Jun;71(6):699–704. doi: 10.1002/jps.2600710623. [DOI] [PubMed] [Google Scholar]
- Simonyi M., Fitos I. Stereoselective binding of a 2,3-benzodiazepine to human serum albumin. Effect of conformation on tofizopam binding. Biochem Pharmacol. 1983 Jun 15;32(12):1917–1920. doi: 10.1016/0006-2952(83)90058-8. [DOI] [PubMed] [Google Scholar]
- Stensrud P., Sjaastad O. Short-term clinical trial of phopranolol in racemic form (Inderal), D-propranolol and placebo in migraine. Acta Neurol Scand. 1976 Mar;53(3):229–232. doi: 10.1111/j.1600-0404.1976.tb04342.x. [DOI] [PubMed] [Google Scholar]
- Tawara K., Kawashima K., Ishikawa H., Yamamoto K., Saito K., Ebihara A., Yoshida S. Pharmacokinetics and pharmacodynamics of propranolol stereoisomers in hyperthyroid patients. Eur J Clin Pharmacol. 1981 Feb;19(3):197–203. doi: 10.1007/BF00561949. [DOI] [PubMed] [Google Scholar]
- von Bahr C., Hermansson J., Lind M. Oxidation of (R)- and (S)-propranolol in human and dog liver microsomes. Species differences in stereoselectivity. J Pharmacol Exp Ther. 1982 Aug;222(2):458–462. [PubMed] [Google Scholar]